Source: Rritual Superfoods Inc.
  • Rritual has increased the size of its C$3,000,000 bought deal offering
  • The underwriter has agreed to purchase 8,000,000 units for aggregate gross proceeds of C$4,000,000
  • The underwriters have been offered an over-allotment option to purchase up to an additional 1,200,000 units for total proceeds of up to $4,600,000
  • The offering is expected to close on or about September 8, 2021
  • Rritual Superfoods is a premium brand in the emerging functional mushroom & adaptogenic superfood market
  • Rritual Superfoods Inc. (RSF) is down 9.26 per cent, trading at $0.46 per share at 4 pm ET

Rritual Superfoods (RSF) is pleased to announce that, due to strong demand, it has increased the size of its previously announced C$3,000,000 bought deal offering.

The underwriter has agreed to purchase 8,000,000 units at a price of C$0.50 per unit for aggregate gross proceeds of C$4,000,000.

The company has agreed to grant the underwriters an over-allotment option to purchase up to an additional 1,200,000 units. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $4,600,000.

The offering is expected to close on or about September 8, 2021.

Rritual Superfoods is the first award-winning, premium brand in the emerging functional mushroom & adaptogenic superfood market.

Rritual Superfoods Inc. (RSF) is down 9.26 per cent, trading at $0.46 per share at 4 pm ET.

More From The Market Online

Siemens & Salesforce deepen AI partnership

Siemens (OTC Pink:SIEGY) and Salesforce (NYSE:CRM) expanded their AI partnership by integrating Agentforce with Teamcentre.

System1 shares jump as MapQuest rides Lake Ontario drama to no. 1 app ranking

System1 stock (NYSE:SST) jumped 25% Thursday as MapQuest surged to the No. 1 navigation app in the U.S. following a spike in downloads.

East Side Games gets lean, trims workforce, re-works portfolio

East Side Games Group (TSX:EAGR) reduced its workforce by approximately 30 employees, or 32% of staff, to improve efficiency and profitability

Restart Life Sciences serves up exponential revenue growth

Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations.